

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/594,127
Confirmation Number	8975
Filing Date	September 25, 2006
First Named Inventor	Akio SUGIHARA
Art Unit	1625
Examiner Name	Niloofar RAHMANI
Attorney Docket Number	Q97391

U.S. PATENTS

U.S. PATENTS					
Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document
					Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

U.S. PATENT APPLICATION PUBLICATIONS

U.S. PATENT APPLICATION PUBLICATIONS					
Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document
					Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No	Foreign Document Number*	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

NON-PATENT LITERATURE DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.
	1.	Philippine Office Action issued June 23, 2010 in corresponding Philippine Application No. 1-2006-501883
	2.	Korean Office Action issued June 16, 2010 in corresponding Korean Application No. 10-2006-7019783
	3.	Third Party Observation issued April 13, 2010 in corresponding European Application No. 05721391.0
	4.	L. YU, "Amorphous pharmaceutical solids: preparation, characterization and stabilization," Advanced Drug Delivery Reviews, Vol. 48, pp. 27-42 (2001)
	5.	B. HANCOCK, "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems," Journal of Pharmaceutical Sciences, Vol. 86, No. 1, pp. 1-12 (1997)
	6.	SOLIFENACIN SUCCINATE: Crystallization experiments [2010]
	7.	E. SHALAEV et al., "How Does Residual Water Affect the Solid-State Degradation of Drugs in the Amorphous State," Journal of Pharmaceutical Sciences, Vol. 85, No. 11, pp. 1137-1141 (1996)

EXAMINER SIGNATURE

Examiner Signature /Niloofar Rahman/ Date Considered 07/26/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NP/

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (PT for Patent Office, US for the USPTO). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of Standard ST, 3. 5 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of Standard ST, 16 if the document is in English. 5 Applicant is to place a check mark here if English language translation is included with this form.